089 Heart Failure management in ambulatory care: what happens beyond hospital discharge? Results from the DEVENIR study  by Assyag, Patrick et al.
© Elsevier Masson SAS. All rights reserved.
 
30 Archives of Cardiovascular Diseases Supplements (2010) 2, 22-38
Conclusion: Rate of betablockers prescription is high at hospital discharge.
Outhospital cardiologists not only pursue but also amplify the care strategies
defined during hospitalisation increasing the proportion of patients receiving
BB and the percentage reaching the target dose.
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Rationale: Heart failure (HF) treatment is often started during hospitalisation
and patients are generally taken over after discharge by outhospital cardiologists.
Objectives: To describe changes in HF treatment implemented by the out-
hospital cardiologist after hospital discharge.
Methods: Cross sectional observational survey with retrospective collec-
tion of data at hospital discharge. Patients must have been diagnosed with HF
and hospitalized for HF within the previous 18 months.
Results: 1 452 patients were included by 412 French outhospital cardiolo-
gists. 1170 have had at least one visit by the cardiologist between hospital dis-
charge (mean delay 5.76±4.51 months). At hospital discharge, target doses
were reached in 10.5% of patients receiving betablockers, 50.9% of patients
with ACEI and in 4.1% of patients with ARB. Doses were increased in 25.3%
of patients receiving betablockers, in 11.7% of patients receiving ACEI and in
10.3% of patients treated with ARB enabling a target dose in 20.4% of patients
with betablockers, and in 83.2% of patients with ACEI or an ARB.
Table. Evolution of treatment after discharge 
Conclusion: Outhospital cardiologists play a critical role in care manage-
ment of HF patients. Not only do they implement but they also amplify the
care strategies defined during hospitalisation.
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Bortezomib is an antitumor therapy for Multiple Myeloma and Non
Hodgkin Lymphoma which incidence is dramatically growing up. This drug
inhibits proteasome activity through action on the 26 S proteasome in mam-
malian cells and leads to apoptosis of tumoral cells. Cardiac toxicity of this
drug is not clearly established and its mechanistic poorly understood. More-
over, the few reports in the update literature are unable to prove a direct
involvement of bortezomib in the occurrence of Acute or Chronic Heart
Failure.
We report the first clinical observation of chronic heart failure which
can be directly related to administration of bortezomib. This relationship is
strongly suggested by the pharmacological Begaud’s score for drug
adverse events with a high degree of imputability. This observation is fur-
ther supported by the report of all other cases of cardiac failure associated
with bortezomib, reported in the French pharmacovigilance database
(table 1).
These reports, the largest cohort available in the international literature,
should lead to a systematically screening for asymptomatic cardiac dis-
eases as well as a rigorous follow up of patients exposed to bortezomib.
The strength of our report is i/ the identification of a case for which the
direct role of bortezomib was demonstrated, ii/ to emphasize with our case
series that this effect occurs more frequently than suspected with a serious
outcome. At hospital 
discharge
At start 
of the survey
Medication 
prescribed 
after discharge
Medication 
discontinued 
after discharge
Betablocker 826 (70,6%) 863 (73,8%) 87 (25,3%)* 50 (6,1%)*
ACEI†† 807 (69,0%) 788 (67,4%) 46 (12,7%)* 65 (8,1%)**
ARB‡ 170 (14,5%) 210 (18,0%) 56 (5,6%)* 16 (9,4%)**
ACEI or ARB 961 (82,1%) 973 (83,2%) - -
*percentages calculated on the number of patients without the treatment 
at hospital discharge;
** percentages calculated on the number of patients without the treatment 
at hospital discharge;†metoprolol, nebivolol, bisoprolol, carvedilol;
††captopril, enalapril, lisinopril, trandolapril, ramipril, perindopril 
(at an accepted target dose of 4mg);‡candesartan, valsartan 
Table 1.  (090)
Patients Age (Year) Gender Disease Cardiac Risk Factor
Prior 
Chemotherpy 
regimens
N°bortezomib 
containing 
cycles
Cumulated 
Dose 
(mg/m2)
Cardiac 
complication death Imputability
#1 79 F MM HTA 0 1 2,64 Acute Heart Failure yes I3
#2 79 F MM 0 1 6 31,2 Acute Heart Failure No I1
#3 71 F MM 0 0 6 31,2 Acute Heart Failure  No I1
#4 54 F MM 0 2 1 4,45 Cardiogenic Shock Yes I1
#5 74 M MM 0 0 1 3,9 Acute Heart Failure Yes I4
#6 61 F MM HTA 4 10 54,3 Acute Heart Failure No I1
#7 69 F MM 0 0 3 15,6 Acute Heart Failure No I1
#8 54 M MM 0 5 3 15 ,6 Acute Heart Failure No I1
Data from the French Pharmacovigilance Database
